NCT07242300

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

A Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) in Adult Patients With Upper Limb Spasticity

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 207 (estimated)
• Sponsor: JHM BioPharma (Tonghua) Co. , Ltd. · Network
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A（Eveotox）in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.

Conditions

• Upper Limb Spasticity (ULS)

Interventions

Type	Name	Description
DRUG	Recombinant Botulinum Toxin Type A for injection	Recombinant Botulinum Toxin Type A for injection
DRUG	Placebo	Placebo will be administered in double-blind fashion during treatment cycle 1 only

Timeline

• Start date: 2026-01-01
• Primary completion: 2026-12-01
• Completion: 2028-01-01
• First posted: 2025-11-21
• Last updated: 2025-11-21

Locations

2 sites across 1 country: China